EUCTR2007-002777-32-DE进行中（未招募）不适用
A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 2-dose schedule (0, 2-month or 0, 6-month) when compared to a standard 3-dose schedule of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine - HPV-048 PRI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 960
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects who the investigator believes that they and/or their parents can and will comply with the requirements of the protocol should be enrolled in the study.
- •A female subject between, and including, 9 and 25 years of age at the time of the first vaccination.
- •Written informed consent/assent obtained from the subject prior to enrolment. For subjects above the legal age of consent, written informed consent must be obtained from the subject. For subjects below the legal age of consent, written informed consent from the subject’s parents/legally acceptable representative, and written informed assent must be obtained from the subject.
- •Healthy subjects as established by medical history and history-oriented clinical examination before entering into the study.
- •Subjects must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be pre-menarcheal; or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 480
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 480
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent,>0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Concurrently participating in another clinical study, at any time during the study period (up to Month 24), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. Days 0 - 29) the first dose of vaccine. Planned administration/administration of routine meningococcal, hepatitis A or B, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccines, up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
- •Pregnant or breastfeeding female.
- •A woman planning to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose.
- •Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (up to Month 24).
- •Previous administration of MPL or AS04 adjuvant.
- •Cancer or autoimmune disease under treatment.
- •Any medically diagnosed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. MPL, AS04.
- •Hypersensitivity to latex (found in syringe-tip cap and plunger).
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature < 37.5°/Axillary temperature < 37.5°C).
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory tests.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period (up to Month 24).
研究者
相似试验
进行中（未招募）
不适用
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years oldHealthy volunteers (immunization against A/California/7/2009 (H1N1)v-like influenza)MedDRA version: 18.0Level: LLTClassification code 10073988Term: Bird fluSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10021433Term: ImmunizationSystem Organ Class: 100000004865EUCTR2011-003512-23-Outside-EU/EEAGlaxoSmithKline Biologicals209
进行中（未招募）
不适用
A vaccine study to evaluate the safety of and the immune protection produced by different doses of two influenza vaccines in healthy children aged at least 6 months but less than 48 monthshealthy volunteers (protection against influenza)MedDRA version: 16.1Level: LLTClassification code 10016794Term: Flu vaccinationSystem Organ Class: 100000004865EUCTR2013-002081-39-FIovartis Vaccines & Diagnostics AG672
已完成
1 期
A study to assess the safety and processing by the body of GDC-5780 in healthy participantsHealthy volunteersISRCTN15259645F. Hoffmann-La Roche Ltd56
进行中（未招募）
不适用
A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbazine, in Subjects with Stage IV MelanomaMalignant Melanoma Stage IVClassification code 10025671EUCTR2004-002130-18-DECentocor B.V.120
进行中（未招募）
1 期
A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbazine, in Subjects with Stage IV MelanomaMalignant Melanoma Stage IVMedDRA version: 9.1 Level: LLT Classification code 10025671 Term: Malignant melanoma stage IVEUCTR2004-002130-18-GBCentocor B.V.